医学
赛马鲁肽
回顾性队列研究
队列
内科学
重症监护医学
糖尿病
内分泌学
2型糖尿病
利拉鲁肽
作者
Jane J. Long,Sukhdeep S. Sahi,Adley Lemke,Jie Na,Oscar A. Garcia Valencia,Pooja Budhiraja,Hani M. Wadei,Vineeth Sudhindran,Roberto Benzo,Matthew M. Clark,Meera Shah,David C. Fipps,P Navrátil,Ahmed Abdelrheem,Afsana Ansari Shaik,Dustin Duffy,Niv Pencovich,Pankaj Shah,Yogish C. Kudva,Aleksandra Kukla,Tayyab S. Diwan
标识
DOI：10.1016/j.eprac.2024.07.008
摘要
Semaglutide, a glucagon-like peptide-1 receptor agonist is approved for weight loss and diabetes treatment, but limited literature exists regarding semaglutide use in patients with advanced chronic kidney disease (CKD). Therefore, this project assessed the safety and efficacy of semaglutide among patients with eGFR (estimated glomerular filtration rate) 15-29 mL/min/1.73m
科研通智能强力驱动
Strongly Powered by AbleSci AI
cocolu
wuyanbiaoqiao
坚强的广山
子车茗
fillippo99
mhl11
sissiarno
iNk
rosalieshi
丰知然
yar
tuanheqi
爱静静
杳鸢
萧水白
从容芮
个性的紫菜
kento
Ganlou
毛豆
皖公网安备34019202002308
